Arcutis Wins FDA Nod To Bring Zoryve Into Younger Kids' Treatment Arsenal

ChainSpy · 2025-12-26T05:55:21+00:00

Arcutis Biotherapeutics has received FDA approval to expand the use of Zoryve cream for treating plaque psoriasis in children as young as 2 years old. This new option, backed by clinical evidence, addresses the challenges of managing the condition in young patients and aims to improve their quality of life.

ChainSpy

2025-12-26 05:55:21

Abstract generation in progress

Arcutis Biotherapeutics just got the green light from the FDA to expand Zoryve (roflumilast) cream into new territory—now targeting children as young as 2 years old for plaque psoriasis treatment.

The regulatory win centers on a PDE4 inhibitor formulation that works once daily as a topical cream. This targeted approach is significant because the PDE4 inhibitor class has shown efficacy in managing inflammatory skin conditions while maintaining a favorable safety profile for sensitive populations.

Clinical Data Paves the Way

The FDA’s acceptance is backed by solid evidence. Arcutis submitted a 4-week Maximal Usage Systemic Exposure (MUSE) study conducted in the 2-to-5-year-old demographic, alongside long-term open-label trial data from children in the same age bracket. The FDA has scheduled a PDUFA action date of June 29, 2026, for its decision.

Currently, Zoryve cream 0.3% carries approval down to age 6 for plaque psoriasis in both adult and pediatric patients. This expansion would fill a meaningful gap in treatment options for the youngest patients.

Why This Matters for Young Patients

“Managing plaque psoriasis in very young children presents unique clinical challenges,” explains Amy Paller, MS, MD, chair of dermatology at Northwestern University Feinberg School of Medicine. The condition frequently flares on sensitive areas—facial skin and skin folds—where standard treatments may not be appropriate or tolerable.

A gentle yet effective PDE4 inhibitor option could provide dermatologists and pediatricians with better tools for early intervention, potentially improving long-term disease control and quality of life for affected children and their families.

The Burden of Pediatric Psoriasis

Psoriasis affects approximately 9 million Americans overall, with symptoms ranging from itching and scaling to redness, flaking, and pain. On darker skin tones, the characteristic plaques can present as grayish, purplish, or brownish lesions, sometimes complicating diagnosis and patient recognition of the condition.

Bringing effective treatment options to younger age groups represents a step forward in comprehensive psoriasis management across the lifespan.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.